Impact of diabetes on clinical outcomes after revascularization with the dual therapy CD34 antibody-covered sirolimus-eluting Combo stent and the sirolimus-eluting Orsiro stent

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelForskningpeer review

Standard

Impact of diabetes on clinical outcomes after revascularization with the dual therapy CD34 antibody-covered sirolimus-eluting Combo stent and the sirolimus-eluting Orsiro stent. / Jakobsen, Lars; Christiansen, Evald H; Freeman, Phillip et al.

I: Catheterization and Cardiovascular Interventions, Bind 99, Nr. 7, 06.2022, s. 1965-1975.

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelForskningpeer review

Harvard

Jakobsen, L, Christiansen, EH, Freeman, P, Kahlert, J, Veien, K, Maeng, M, Raungaard, B, Ellert, J, Kristensen, SD, Christensen, MK, Terkelsen, CJ, Thim, T, Eftekhari, A, Jensen, RV, Støttrup, NB, Junker, A, Hansen, HS & Jensen, LO 2022, 'Impact of diabetes on clinical outcomes after revascularization with the dual therapy CD34 antibody-covered sirolimus-eluting Combo stent and the sirolimus-eluting Orsiro stent', Catheterization and Cardiovascular Interventions, bind 99, nr. 7, s. 1965-1975. https://doi.org/10.1002/ccd.30175

APA

Jakobsen, L., Christiansen, E. H., Freeman, P., Kahlert, J., Veien, K., Maeng, M., Raungaard, B., Ellert, J., Kristensen, S. D., Christensen, M. K., Terkelsen, C. J., Thim, T., Eftekhari, A., Jensen, R. V., Støttrup, N. B., Junker, A., Hansen, H. S., & Jensen, L. O. (2022). Impact of diabetes on clinical outcomes after revascularization with the dual therapy CD34 antibody-covered sirolimus-eluting Combo stent and the sirolimus-eluting Orsiro stent. Catheterization and Cardiovascular Interventions, 99(7), 1965-1975. https://doi.org/10.1002/ccd.30175

CBE

MLA

Vancouver

Author

Bibtex

@article{1dbe6e7db43e4a168b724b182b689d9f,
title = "Impact of diabetes on clinical outcomes after revascularization with the dual therapy CD34 antibody-covered sirolimus-eluting Combo stent and the sirolimus-eluting Orsiro stent",
abstract = "OBJECTIVES: To compare the efficacy and safety of the dual therapy CD34 antibody-covered sirolimus-eluting Combo stent (DTS) and the sirolimus-eluting Orsiro stent (SES) in patients with and without diabetes mellitus (DM) included in the Scandinavian Organization for Randomized Trials with Clinical Outcome (SORT OUT) X study.BACKGROUND: The incidence of target lesion failure (TLF) after treatment with modern drug-eluting stents has been reported to be significantly higher in patients with DM when compared to patients without DM. Thus, whether the results from the SORT OUT X study apply to patients with and without DM remains unknown.METHODS: In total 3146 patients were randomized to stent implantation with DTS (n = 1578; DM: n = 279) or SES (n = 1568; DM: n = 271). The primary end point, TLF, was a composite of cardiac death, target-lesion myocardial infarction (MI), or target lesion revascularization (TLR) within 1 year.RESULTS: At 1 year, the rate of TLF was increased in the DTS group compared to the SES group, both among patients with DM (9.3% vs. 4.8%; risk difference: 4.5%; incidence rate ratio: 1.99, 95% confidence interval [CI]: 1.02-3.90) and without DM (5.7% vs. 3.5%; incidence rate ratio: 1.67, 95% CI: 1.15-2.42). The differences were mainly explained by higher rates of TLR.CONCLUSION: Compared to the SES, the DTS was associated with an increased risk of TLF at 12 months in patients with and without DM. The differences were mainly explained by higher rates of TLR, whereas rates of cardiac death and target lesion MI did not differ significantly between the two stent groups in patients with or without DM.",
keywords = "diabetes, randomized controlled trial, stent comparison, target lesion failure, TRIALS, ANGIOGRAPHY, IMPLANTATION, UNSELECTED PATIENTS, SORT, CORONARY STENT, MELLITUS, HYPERPLASIA, Percutaneous Coronary Intervention/adverse effects, Sirolimus/adverse effects, Coronary Artery Disease/drug therapy, Humans, Treatment Outcome, Diabetes Mellitus/diagnosis, Prosthesis Design, Absorbable Implants, Myocardial Infarction/etiology, Death, Stents",
author = "Lars Jakobsen and Christiansen, {Evald H} and Phillip Freeman and Johnny Kahlert and Karsten Veien and Michael Maeng and Bent Raungaard and Julia Ellert and Kristensen, {Steen D} and Christensen, {Martin K} and Terkelsen, {Christian J} and Troels Thim and Ashkan Eftekhari and Jensen, {Rebekka V} and St{\o}ttrup, {Nicolaj B} and Anders Junker and Hansen, {Henrik S} and Jensen, {Lisette O}",
note = "{\textcopyright} 2022 The Authors. Catheterization and Cardiovascular Interventions published by Wiley Periodicals LLC.",
year = "2022",
month = jun,
doi = "10.1002/ccd.30175",
language = "English",
volume = "99",
pages = "1965--1975",
journal = "Catheterization and Cardiovascular Interventions",
issn = "1522-1946",
publisher = "JohnWiley & Sons, Inc.",
number = "7",

}

RIS

TY - JOUR

T1 - Impact of diabetes on clinical outcomes after revascularization with the dual therapy CD34 antibody-covered sirolimus-eluting Combo stent and the sirolimus-eluting Orsiro stent

AU - Jakobsen, Lars

AU - Christiansen, Evald H

AU - Freeman, Phillip

AU - Kahlert, Johnny

AU - Veien, Karsten

AU - Maeng, Michael

AU - Raungaard, Bent

AU - Ellert, Julia

AU - Kristensen, Steen D

AU - Christensen, Martin K

AU - Terkelsen, Christian J

AU - Thim, Troels

AU - Eftekhari, Ashkan

AU - Jensen, Rebekka V

AU - Støttrup, Nicolaj B

AU - Junker, Anders

AU - Hansen, Henrik S

AU - Jensen, Lisette O

N1 - © 2022 The Authors. Catheterization and Cardiovascular Interventions published by Wiley Periodicals LLC.

PY - 2022/6

Y1 - 2022/6

N2 - OBJECTIVES: To compare the efficacy and safety of the dual therapy CD34 antibody-covered sirolimus-eluting Combo stent (DTS) and the sirolimus-eluting Orsiro stent (SES) in patients with and without diabetes mellitus (DM) included in the Scandinavian Organization for Randomized Trials with Clinical Outcome (SORT OUT) X study.BACKGROUND: The incidence of target lesion failure (TLF) after treatment with modern drug-eluting stents has been reported to be significantly higher in patients with DM when compared to patients without DM. Thus, whether the results from the SORT OUT X study apply to patients with and without DM remains unknown.METHODS: In total 3146 patients were randomized to stent implantation with DTS (n = 1578; DM: n = 279) or SES (n = 1568; DM: n = 271). The primary end point, TLF, was a composite of cardiac death, target-lesion myocardial infarction (MI), or target lesion revascularization (TLR) within 1 year.RESULTS: At 1 year, the rate of TLF was increased in the DTS group compared to the SES group, both among patients with DM (9.3% vs. 4.8%; risk difference: 4.5%; incidence rate ratio: 1.99, 95% confidence interval [CI]: 1.02-3.90) and without DM (5.7% vs. 3.5%; incidence rate ratio: 1.67, 95% CI: 1.15-2.42). The differences were mainly explained by higher rates of TLR.CONCLUSION: Compared to the SES, the DTS was associated with an increased risk of TLF at 12 months in patients with and without DM. The differences were mainly explained by higher rates of TLR, whereas rates of cardiac death and target lesion MI did not differ significantly between the two stent groups in patients with or without DM.

AB - OBJECTIVES: To compare the efficacy and safety of the dual therapy CD34 antibody-covered sirolimus-eluting Combo stent (DTS) and the sirolimus-eluting Orsiro stent (SES) in patients with and without diabetes mellitus (DM) included in the Scandinavian Organization for Randomized Trials with Clinical Outcome (SORT OUT) X study.BACKGROUND: The incidence of target lesion failure (TLF) after treatment with modern drug-eluting stents has been reported to be significantly higher in patients with DM when compared to patients without DM. Thus, whether the results from the SORT OUT X study apply to patients with and without DM remains unknown.METHODS: In total 3146 patients were randomized to stent implantation with DTS (n = 1578; DM: n = 279) or SES (n = 1568; DM: n = 271). The primary end point, TLF, was a composite of cardiac death, target-lesion myocardial infarction (MI), or target lesion revascularization (TLR) within 1 year.RESULTS: At 1 year, the rate of TLF was increased in the DTS group compared to the SES group, both among patients with DM (9.3% vs. 4.8%; risk difference: 4.5%; incidence rate ratio: 1.99, 95% confidence interval [CI]: 1.02-3.90) and without DM (5.7% vs. 3.5%; incidence rate ratio: 1.67, 95% CI: 1.15-2.42). The differences were mainly explained by higher rates of TLR.CONCLUSION: Compared to the SES, the DTS was associated with an increased risk of TLF at 12 months in patients with and without DM. The differences were mainly explained by higher rates of TLR, whereas rates of cardiac death and target lesion MI did not differ significantly between the two stent groups in patients with or without DM.

KW - diabetes

KW - randomized controlled trial

KW - stent comparison

KW - target lesion failure

KW - TRIALS

KW - ANGIOGRAPHY

KW - IMPLANTATION

KW - UNSELECTED PATIENTS

KW - SORT

KW - CORONARY STENT

KW - MELLITUS

KW - HYPERPLASIA

KW - Percutaneous Coronary Intervention/adverse effects

KW - Sirolimus/adverse effects

KW - Coronary Artery Disease/drug therapy

KW - Humans

KW - Treatment Outcome

KW - Diabetes Mellitus/diagnosis

KW - Prosthesis Design

KW - Absorbable Implants

KW - Myocardial Infarction/etiology

KW - Death

KW - Stents

U2 - 10.1002/ccd.30175

DO - 10.1002/ccd.30175

M3 - Journal article

C2 - 35384254

VL - 99

SP - 1965

EP - 1975

JO - Catheterization and Cardiovascular Interventions

JF - Catheterization and Cardiovascular Interventions

SN - 1522-1946

IS - 7

ER -